Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FL115 Alone or with BCG in NMIBC
NCT07122414Phase 2Recruiting
- Sponsor
- Forlong Biotechnology
- Start
- Aug 2024
- Primary completion
- Oct 2027
- Modality
- Cytokines & Interferons, Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of FL-115 in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Forlong Biotechnology. Primary endpoints: Maximum Tolerated Dose up to 15 months, Recommended Phase 2 Dose up to 15 months and 3 more. Started Aug 2024; status: recruiting.
02
Drugs
FL-115
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07122414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07122414.